NASCOP and the Kenya HIV Programme: From PEPFAR to U=U, Treatment Coverage, Prevention Innovations and the Path to Epidemic Control

Kenya's HIV/AIDS programme is one of the most extensive public-health programmes in Africa and one of the most successful in shifting the trajectory of the epidemic over the past two decades. Approximately 1.4 million Kenyans are living with HIV (per the most recent estimates from the National AIDS Control Council and the National AIDS and STI Control Programme — NASCOP). The Kenya HIV programme is delivered through NASCOP under the Ministry of Health, with substantial support from the US President's Emergency Plan for AIDS Relief (PEPFAR), the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Bill & Melinda Gates Foundation, UNAIDS, the World Health Organization, and the broader development partner community. The programme has produced documented dramatic reductions in HIV-related mortality (from the peak of over 100,000 deaths annually in the early 2000s to current rates substantially below) and has substantially reduced new infection rates. The contemporary programme operates under the "Undetectable equals Untransmittable" (U=U) framework — the scientific consensus that people with HIV on effective antiretroviral therapy with undetectable viral loads cannot sexually transmit HIV — and the broader 95-95-95 targets (95 per cent of people living with HIV knowing their status, 95 per cent of those knowing their status on treatment, 95 per cent of those on treatment achieving viral suppression). Kenya has progressively approached these targets through sustained intervention. This guide walks through the epidemic history, the NASCOP programme architecture, treatment coverage, prevention innovations, the PEPFAR partnership, and the path to epidemic control.

The Epidemic History

HIV/AIDS emerged in Kenya in the early 1980s with progressively increasing case incidence through the 1990s and the peak of the epidemic in the late 1990s-early 2000s. At the epidemic peak, Kenyan HIV prevalence among the adult population (15-49 years) approached 13 per cent — among the highest globally. The peak mortality in the early 2000s before widespread antiretroviral therapy availability was approximately 130,000 annual deaths. The launch of PEPFAR in 2003 and the broader global response to the African HIV epidemic produced substantial scale-up of antiretroviral therapy from 2004 onward, with the progressive expansion of testing, treatment, and prevention services.

NASCOP Programme Architecture

NASCOP coordinates the Kenya HIV programme. The programme operates through: HIV testing services at health facilities, community sites, and the broader population-level testing infrastructure including HIV self-testing; antiretroviral treatment provision at over 1,500 ART treatment sites across all 47 counties; prevention-of-mother-to-child transmission (PMTCT) services integrated into antenatal care; voluntary medical male circumcision (VMMC) particularly in the western Kenya high-prevalence counties; key population (sex workers, men who have sex with men, people who inject drugs, transgender people) interventions through specialised programming; pre-exposure prophylaxis (PrEP) for HIV-negative individuals at elevated risk; post-exposure prophylaxis (PEP) for occupational and sexual exposure; comprehensive condom programming; the broader behavioural-change communication; and the integrated tuberculosis-HIV programme given the substantial co-infection burden.

Treatment Coverage

Kenya has progressively achieved substantial treatment coverage. Recent estimates indicate that approximately 96 per cent of people living with HIV in Kenya know their status, approximately 97 per cent of those who know their status are on antiretroviral therapy, and approximately 95 per cent of those on treatment have achieved viral suppression — together approaching the UNAIDS 95-95-95 targets. The treatment regimens have progressively shifted to the more effective and tolerable Dolutegravir-based first-line regimens that have substantially improved both clinical outcomes and patient experience. Pediatric HIV treatment has expanded with the pediatric Dolutegravir formulations now available.

PEPFAR Partnership

The US President's Emergency Plan for AIDS Relief (PEPFAR) — launched in 2003 by the George W Bush administration — is one of the largest commitments by any country to a single disease in human history. Kenya is one of the principal PEPFAR partner countries, with cumulative US investment in the Kenya HIV programme of several billion dollars over the programme's lifetime. PEPFAR funds substantial elements of the testing, treatment, prevention, laboratory infrastructure, supply chain, health workforce, and the broader programme infrastructure. The PEPFAR partnership has been one of the principal foundations of Kenya's HIV-response success.

Prevention Innovations

The Kenya HIV programme has progressively integrated prevention innovations. Voluntary medical male circumcision — based on the documented protective effect of approximately 60 per cent reduction in HIV acquisition among circumcised men — has been substantially scaled up in the high-prevalence western Kenya counties with cumulative VMMC procedures in the millions. Pre-exposure prophylaxis (PrEP) with oral Tenofovir-Emtricitabine (Truvada) is offered to HIV-negative individuals at elevated risk including HIV-negative partners in serodifferent couples, sex workers, men who have sex with men, transgender people, and selected adolescent girls and young women in high-prevalence areas. The newer long-acting injectable PrEP using Cabotegravir (every two months) has been progressively introduced, offering substantial adherence advantages over daily oral PrEP. The Dapivirine vaginal ring offers another option particularly for women. HIV self-testing has substantially expanded access to confidential testing.

Prevention of Mother-to-Child Transmission

The PMTCT programme has produced one of the most dramatic public-health successes. Vertical HIV transmission from infected pregnant women to their infants — historically transmitting at rates of 25-45 per cent without intervention — has been reduced to under 5 per cent through the integrated PMTCT package (antiretroviral therapy for HIV-positive pregnant women during pregnancy, delivery, and breastfeeding; HIV-exposed infant prophylaxis; safe delivery practices; and the broader integrated programme). The integration of PMTCT into the antenatal-care platform has produced substantial scaling.

The U=U Framework

The "Undetectable equals Untransmittable" (U=U) framework — based on substantial scientific evidence from large studies including HPTN 052, PARTNER, PARTNER 2, and the broader research base — confirms that people living with HIV who achieve and maintain undetectable viral loads on effective antiretroviral therapy cannot sexually transmit HIV. The U=U framework has substantial implications for both clinical practice (motivating treatment adherence) and broader societal attitudes (reducing stigma associated with HIV). Kenya has progressively integrated U=U communication into the broader HIV programme messaging.

Key Populations

HIV prevalence is substantially elevated among key populations including sex workers, men who have sex with men, people who inject drugs, transgender people, and people in prisons and other closed settings. The Kenya HIV programme provides specialised programming for these populations through community-led organisations, drop-in centres, dedicated clinical services, and the broader supportive framework. The programming operates in the context of the complex legal and social environment for sexual-minority populations and the broader human-rights considerations.

The Path to Epidemic Control

Kenya has progressively approached the technical definition of epidemic control — meaning that new HIV infections fall below the rate of HIV-related deaths, producing year-over-year reduction in the population living with HIV. Several counties have achieved or are approaching epidemic control. The continued path requires sustained intervention scale, the addressing of remaining gaps (particularly among adolescent girls and young women in the high-prevalence western Kenya counties), the integration of new prevention tools, and the broader strengthening of the health system. The 2030 UNAIDS target of ending AIDS as a public health threat by 2030 remains the broader programmatic horizon.

The Bigger Picture

The Kenya HIV programme is one of the most successful public-health programmes in African history. The combination of sustained political commitment, substantial international partnership, scientific innovation, community engagement, and the broader integrated programme architecture has produced documented dramatic improvements in HIV-related health outcomes for the 1.4 million Kenyans living with HIV and the broader population at risk. For healthcare professionals, people living with HIV, families and communities affected by HIV, and the broader public-health community, the Kenya HIV experience represents one of the most consequential public-health interventions in modern Kenyan history.

The National AIDS and STI Control Programme publishes the programme framework. The National AIDS Control Council coordinates the broader policy and multi-sectoral response.